

Board of Directors: 10.5.18

Agenda Item: Bo.5.18.20

Report from the Major Projects Committee - 28 February 2018

Presented by:	Amjad Pervez, Non-Executive Director	Author:	Jacqui Maurice, Head of Corporate Governance
Previously considered by:	n/a		

Key points	Purpose:
1. This paper provides a brief summary of the key matters that were discussed at the meeting of the Major Projects Committee which was held on 28 February 2018 .	To discuss and note

Executive Summary:
The purpose of the Major Projects Committee, as set out in its Terms of Reference, is to provide detailed scrutiny of the Foundation Trust's major projects in order to provide assurance and, if necessary, raise concerns or make recommendations to the Board of Directors.

Financial implications:

Regulatory relevance:

Monitor:	
-----------------	--

Equality Impact / Implications:	Is there likely to be any impact on any of the protected characteristics? (Age, Disability, Gender, Gender Reassignment, Pregnancy and Maternity, Race, Religion or Belief, Sexual Orientation, Health Inequalities, Human Rights) Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> If yes, what is the mitigation against this?
--	--

Other:	
---------------	--

Strategic Objective:	To deliver our financial plan and key performance targets
<i>Reference to Strategic Objective(s) this paper relates to</i>	To provide outstanding care for patients
	To be a continually learning organisation

Major Projects Committee

1. Introduction

The purpose of this paper is to advise the Board of Directors of the key matters discussed and a brief summary of agenda items of the Committee which was held on 28 February 2018.

Board of Directors: 10.5.18

Agenda Item: Bo.5.18.20

2. Key Matters discussed

- WYAAT: Special Purpose Vehicles
- EPR Update
- Pathology Joint Venture Update
- Wolfson Centre for Applied Health Research
- 18/19 Capital Budget Setting Report

3. Agenda

3.1 Major Projects Committee Dashboard

The Committee agreed that there would be no requirement for a dashboard for this Committee.

3.2 WYAAT: Special Purpose Vehicles

The Committee noted the paper that had gone to the board requesting the development of a business case with a clearer focus on Bradford and patient. Committee noted that all options would be considered in March via an engagement plan which would include consultation with stakeholders and Foundation Trust employees.

3.3 EPR Update

EPR was now at month five of the six-month embedding time-line. It is expected that the majority of staff have become accustomed to the change. There are some small pieces of work that are all expected to be complete by early February 2018. The Health Information Exchange which is in the planning stage.

3.4 Pathology Joint Venture Update

The Committee noted that:

- NHS Improvement is reviewing the consolidation of a number of Pathology departments across West Yorkshire.
- WYATT would like to include Bradford Teaching Hospitals NHS Foundation Trust and Airedale NHS Foundation Trust in the Joint Venture which is attracting interest from other Trusts.
- Pathology is now reporting via EPR. Safety benefits are being realised.

3.5 Wolfson Centre for Applied Health Research

Planning permission has been secured. The first part of the project will start in April 2018 with completion expected in May /June 2019.

Board of Directors: 10.5.18

Agenda Item: Bo.5.18.20

Positive progress has been made with regard to Operational Governance around the centre and, the development of the research portfolio amongst the academics from the Universities and the Trust.

3.6 Major Projects Committee Work Plan 2018/19

The Work Plan was accepted subject to the removal of the Major Projects dashboard.

3.7 18/19 Capital Budget Setting Report

The Committee discussed the report and sought assurances and information with regard to;

- Equipment replacement schedules and,
- Frequency surrounding the checking of manufacturers guarantees.
- Age of the equipment and
- Trust investment in maintenance contracts
- Areas under review for improvement for capital investment (in relation to progress and actions relating to CQC standings/inspection outcomes)

3.8 Matters to share with other Committees

- Pathology Joint Venture
- Vascular Arterial Centre
- Special Vehicles Project
- EPR Productivity

3.9 Matters to Escalate to the Corporate Risk Register and the Board of Directors.

There were no items to escalate to the corporate risk register or the Board of Directors.

4. Recommendation

The Board of Directors is asked to note the above points.